4,329
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Novartis's recently active trials. Comparator arms are excluded.
- Alpelisib5 trials
- Secukinumab4 trials
- Ianalumab4 trials
- Remibrutinib4 trials
- [177Lu]Lu-DOTA-TATE3 trials
- AAA6173 trials
Upcoming readouts
Next primary completion dates among Novartis's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jan 2027APPEAR-C3G: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Phase 3
- Feb 2027RECLAIM: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults…Phase 3
- Mar 2027CRYPTONITE: Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Mode…Phase 2
- Apr 2027A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatr…Phase 2
- Jul 2027A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fe…Phase 2
- Jul 2027Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Child…Phase 2
Top therapeutic areas
Conditions studied most often across Novartis's recently active trials.
- Prostatic Neoplasms, Castration-Resistant4 trials
- Breast Cancer4 trials
- Hidradenitis Suppurativa3 trials
- Plaque Psoriasis2 trials
- Cryptosporidiosis2 trials
- IgA Nephropathy2 trials
Novartis trials
The 50 most significant of Novartis's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.NCT06379217[68Ga]Ga-PSMA-11 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 31 est. | 24 Aug 2026 |
| ScreenXModifying PEST for Psoriatic Arthritis ScreeningNCT06382051PEST Screening group | Na | Locked · track to reveal | OngoingRecruiting | 502 est. | 28 Aug 2026 |
| CATTALYSTA Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer PatientsNCT07710716 | — | Locked · track to reveal | OngoingActive, not recruiting | 3,000 est. | 30 Sept 2026 |
| Contralateral Claims Study of Clareon Vivity ProNCT07484191Clareon Vivity Pro IOL | Na | Locked · track to reveal | OngoingRecruiting | 231 est. | Oct 2026 |
| V-PLAQUECoronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsNCT05360446Inclisiran sodium 300 mg | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 609 est. | 26 Oct 2026 |
| VICTORION-LEAPA Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabNCT07543731 | — | Locked · track to reveal | OngoingRecruiting | 5,995 est. | 30 Oct 2026 |
| PRISMPluvicto Real-world Investigation in Survival in Metastatic CRPCNCT07697989 | — | Not yet scored | OngoingNot yet recruiting | 1,085 est. | 31 Oct 2026 |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upNCT05677451LOU064 (blinded) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 100 est. | 3 Nov 2026 |
| A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate CancerNCT07677254 | — | Not yet scored | OngoingRecruiting | 17,111 est. | 30 Nov 2026 |
| A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide TetraxetanNCT07677267 | — | Not yet scored | OngoingRecruiting | 1,067 est. | 30 Nov 2026 |
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionNCT06004661AAA617 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 23 est. | 14 Dec 2026 |
| ROUTE-C3GA Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNCT07598448 | — | Not yet scored | OngoingNot yet recruiting | 35 est. | 15 Dec 2026 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationNCT07626281Inclisiran formulation containing PS80 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | 21 Dec 2026 |
| PSMACareA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNCT05849298AAA617 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 49 est. | 23 Dec 2026 |
| SEC-HOPEA Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLDNCT07683065 | — | Not yet scored | OngoingRecruiting | 150 est. | 15 Jan 2027 |
| EPIK-B5Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.NCT05038735Alpelisib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 210 est. | 28 Jan 2027 |
| APPEAR-C3GStudy of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.NCT04817618iptacopan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 98 est. | 29 Jan 2027 |
| RECLAIMA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesNCT06868212Remibrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 400 est. | 22 Feb 2027 |
| CRYPTONITEStudy Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy AdultsNCT07249463Cryptosporidium parvum oocysts (ABO809) | Phase 2 | Locked · track to reveal | OngoingRecruiting | 80 est. | 2 Mar 2027 |
| ANIMALong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.NCT05921994secukinumab | — | Not yet scored | OngoingActive, not recruiting | 436 est. | 31 Mar 2027 |
| A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseNCT07203001MAS825 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 22 Apr 2027 |
| A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric ParticipantsNCT07716410 | — | Not yet scored | OngoingRecruiting | 30 est. | 19 May 2027 |
| Clinical Evaluation of a Novel Trifocal IOLNCT07587138LPYWT0 | Na | Locked · track to reveal | OngoingNot yet recruiting | 66 est. | Jul 2027 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07047118JSB462 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 138 est. | 16 Jul 2027 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverNCT06006559EYU688 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 108 est. | 22 Jul 2027 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With AsthmaNCT05222529Glycopyrronium bromide 25ug | Phase 2 | Locked · track to reveal | OngoingRecruiting | 42 est. | 30 Jul 2027 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisNCT06470048Ianalumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 30 Jul 2027 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaNCT06865651Remibrutinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 44 est. | 23 Aug 2027 |
| VICTORION-2PStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseNCT05030428Inclisiran sodium 300 mg | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 17,004 est. | 13 Oct 2027 |
| Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT04747613Iptacopan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 208 est. | 18 Oct 2027 |
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)NCT07681271LOU064 | Phase 2 | Not yet scored | OngoingRecruiting | 80 est. | 7 Dec 2027 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseaseNCT07235059OJR520 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 112 est. | 21 Jan 2028 |
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisNCT07604324DCY636 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 63 est. | 27 Jan 2028 |
| A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaNCT05562466QMF149 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 200 est. | 1 Feb 2028 |
| Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerNCT06517719lutetium (177Lu) vipivotide tetraxetan | — | Not yet scored | OngoingRecruiting | 500 est. | 1 Feb 2028 |
| ADD-VANTAGELp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDNCT06813911Pelacarsen | Phase 3 | Locked · track to reveal | OngoingRecruiting | 340 est. | 3 Feb 2028 |
| A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved RemissionNCT05622708Secukinumab | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 240 est. | 8 Feb 2028 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabNCT05142696[177Lu]Lu-DOTA-TATE | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 55 est. | 7 Mar 2028 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesNCT07340190pelabresib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 24 est. | 9 Mar 2028 |
| VAY2EXPLOREA Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)NCT07421167ianalumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 164 est. | 1 Apr 2028 |
| A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseNCT06546670ITU512 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 161 est. | 1 May 2028 |
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaNCT07713602Coartem® Baby | Phase 4 | Not yet scored | OngoingNot yet recruiting | 20 est. | 4 May 2028 |
| MANIFEST-3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727Pelabresib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 460 est. | 17 May 2028 |
| EPIK-L1Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.NCT05948943Alpelisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 232 est. | 31 May 2028 |
| VITESSA Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoNCT07431177GIA632 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 210 est. | 6 Jun 2028 |
| Fabhalta Capsules Specified Drug-use SurveyNCT07156149 | — | Not yet scored | OngoingActive, not recruiting | 33 est. | 30 Jun 2028 |
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)NCT06997588Alpelisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 104 est. | 2 Aug 2028 |
| CONFIRMHydrus® Microstent New Enrollment Post-Approval StudyNCT04553523Hydrus Microstent | Na | Locked · track to reveal | OngoingRecruiting | 545 est. | Aug 2028 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsNCT06726148ECI830 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 280 est. | 25 Sept 2028 |
| ANIMA - ItalyLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian PopulationNCT07543419 | — | Not yet scored | OngoingRecruiting | 250 est. | 30 Sept 2028 |